Tissue destruction induced by Porphyromonas gingivalis infection in a mouse chamber model is associated with host tumor necrosis factor generation.
Intrachamber challenge with Porphyromonas gingivalis strain 381 in a mouse subcutaneous chamber model results in a local infection that progresses to exfoliation of the chambers within 15 days. This study was designed to elucidate the contribution of host reactions to tissue destruction manifested by chamber exfoliation in animals infected with P. gingivalis. Chamber fluids showed increasing levels of prostaglandin E(2) with infection, and the levels of tumor necrosis factor (TNF) in chamber fluids peaked just before chamber exfoliation. Intraperitoneal injection of a TNF inhibitor, thalidomide (TH), reduced the number of exfoliated chambers, while indomethacin had no effect. Exogenous TNF in chambers without bacterial infection did not cause chamber exfoliation but induced neutrophil infiltration. In a dual-chamber model, two chambers were implanted in the same mouse. One chamber was infected with P. gingivalis, and 9 days later exogenous TNF was added to the other chamber. Altogether, 66.67% of uninfected chambers were exfoliated between day 11 and day 16, although no bacteria were recovered from uninfected chambers. TH treatment alleviated both infected and uninfected chamber exfoliation. In this study, tissue destruction caused by P. gingivalis 381 infection was due to the elevation of the TNF levels and not due to local bacterial activities. Our results further indicate that local infection by P. gingivalis 381, a nondisseminating strain, actually has systemic effects on the host pathological outcome.
Lin
Yuh-Yih
YY
Department of Dentistry, Chung Shan Medical University, No. 110 Chien-Kuo N. Road, Taichung, 402, Taiwan. yuhyih@csmu.edu.tw
Huang
Jan-Hung
JH
Lai
Yo-Yin
YY
Huang
Han-Ching
HC
Hu
Suh-Woan
SW
D000818:Animals; D016866:Bacteroidaceae Infections / Q000276:immunology* / Q000473:pathology*; D002452:Cell Count; D016207:Cytokines / Q000032:analysis; D015232:Dinoprostone / Q000032:analysis / Q000037:antagonists & inhibitors / Q000494:pharmacology; D004195:Disease Models, Animal; D051379:Mice; D016966:Porphyromonas gingivalis / Q000302:isolation & purification; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000378:metabolism* / Q000494:pharmacology
D016207:Cytokines; D014409:Tumor Necrosis Factor-alpha; D015232:Dinoprostone